Immunotherapy of cancer using cytokine gene-modified tumor vaccines

Eli Gilboa, H. K. Lyerly, Johannes Vieweg, Shiro Saito

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Distant metastasis is the major cause for therapeutic failures in clinical oncology. Active immunotherapy of patients with low tumor burden would not only contribute to further reduction of the remaining tumor burden to subclinical levels, but it would also establish a constant state of immunity, i.e. immunological memory, that could protect the patient from recurrence of disease. Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genitically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines such as IL-2, IL-6, IFN-γ or GM-CSF were capable of inducing the regression of a preexisting tumor burden and cure animals from their disease. Moreover, in some instances the cured animals have retained immunological memory, as indicated by the fact that such animals have resisted a second challenge with the parental tumor cells. Induction of potent immune responses in tumor bearing animals against nonimmunogenic tumors supports the view that active immunization of cancer patients deserves consideration despite lack of demonstrable immunogenicity in many human tumors.

Original languageEnglish (US)
Pages (from-to)409-417
Number of pages9
JournalSeminars in Cancer Biology
Volume5
Issue number6
StatePublished - Dec 1 1994
Externally publishedYes

Keywords

  • Cytokine
  • Gene therapy
  • Immunotherapy
  • Tumor vaccines

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Immunotherapy of cancer using cytokine gene-modified tumor vaccines'. Together they form a unique fingerprint.

  • Cite this